Photo from LUNGevity Foundation/X
Jun 1, 2024, 11:46
Phase 2 study OptiTROP-Lung01 had promising results in patients with advanced NSCLC – LUNGevity Foundation
LUNGevity Foundation shared on X/Twitter:
“Phase 2 study (OptiTROP-Lung01) had promising results in patients with advanced NSCLC . Phase 3 study versus immunotherapy is underway. More ADC studies are needed.”
Source: LUNGevity Foundation/X
